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AbstrACt
Purpose The ThRombolysis in Ischemic Stroke Patients 
(TRISP) collaboration aims to address clinically relevant 
questions about safety and outcomes of intravenous 
thrombolysis (IVT) and endovascular thrombectomy. 
The findings can provide observational information on 
treatment of patients derived from everyday clinical 
practice.
Participants TRISP is an open, investigator-driven 
collaborative research initiative of European stroke 
centres with expertise in treatment with revascularisation 
therapies and maintenance of hospital-based registries. All 
participating centres made a commitment to prospectively 
collect data on consecutive patients with stroke treated 
with IVT using standardised definitions of variables and 
outcomes, to assure accuracy and completeness of the 
data and to adapt their local databases to answer novel 
research questions.
Findings to date Currently, TRISP comprises 18 centres and 
registers >10 000 IVT-treated patients. Prior TRISP projects 
provided evidence on the safety and functional outcome in 
relevant subgroups of patients who were excluded, under-
represented or not specifically addressed in randomised 
controlled trials (ie, pre-existing disability, cervical artery 
dissections, stroke mimics, prior statin use), demonstrated 
deficits in organisation of acute stroke care (ie, IVT during 
non-working hours, effects of onset-to-door time on 
onset-to-needle time), evaluated the association between 
laboratory findings on outcome after IVT and served to 
develop risk estimation tools for prediction of haemorrhagic 
complications and functional outcome after IVT.
Future plans Further TRISP projects to increase 
knowledge of the effect and safety of revascularisation 
therapies in acute stroke are ongoing. TRISP welcomes 
participation and project proposals of further centres 
fulfilling the outlined requirements. In the future, TRISP will 
be extended to include patients undergoing endovascular 
thrombectomy.
IntroduCtIon   
Intravenous thrombolysis (IVT) with recom-
binant tissue plasminogen activator (rtPA) 
for ischaemic stroke markedly improves func-
tional outcome with a strong impact of time to 
treatment.1 The pivotal National Institute of 
Neurological Disorders and Stroke (NINDS) 
trial in 1995 and more recently the individual 
patient data meta-analyses of subsequent 
randomised controlled trials (RCTs) proved 
safety and efficacy of IVT in acute ischaemic 
stroke.2 3
Implementation of IVT in acute medical 
treatment for ischaemic stroke has profoundly 
changed clinical routine. However, selection 
of patients for IVT in RCTs was based on 
strict criteria in order to exclude patients with 
presumably (1) low probability of favourable 
outcome per se or (2) high bleeding risk.4 5 
The current exclusion criteria listed in the 
American Heart Association and American 
Stroke Association 2013 acute stroke manage-
ment guidelines are still based largely on 
strengths and limitations of this study
 ► The Thrombolysis in Ischemic Stroke (TRISP) collab-
oration offers a platform to pool individual patient 
data from prospective registries of patients with 
ischaemic stroke undergoing revascularisation 
therapies.
 ► TRISP will provide data from everyday clinical prac-
tice and address clinically important questions about 
safety and outcomes of patients with ischaemic 
stroke treated with thrombolysis who are neither 
covered by randomised controlled trials nor other 
large-scale registers.
 ► The large sample size (currently  >10 000 from 
18 centres), high completeness of data and stan-
dardised data ascertainment are strengths of TRISP.
 ► Data are not monitored, treatment decisions are 
made individually and not randomised, and most 
centres do not collect data on control patients who 
were not treated with thrombolysis.
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the criteria listed in the NINDS trial, with only minor 
modifications over time.5 Many criteria addressed in the 
guidelines were adapted from the cardiologic literature 
or from basic science publications.5 This overall conser-
vative approach in selecting patients suitable for IVT is 
controversial as it is often unproven whether patients not 
meeting the established eligibility criteria do not benefit 
from IVT. As a consequence, the practice pattern of IVT 
usage has been shown to vary largely across centres.6 
Furthermore, a restrictive approach in using IVT is 
likely to contribute to low IVT rates, especially in centres 
with reduced service levels.7 Systematically ascertained, 
comprehensive and high-quality observational data are 
useful to both (1) challenge or (2) confirm the clinical 
usefulness of commonly used but often arbitrary eligi-
bility criteria. Of note, approximately half of patients 
have at least one contraindication or warning in large 
dedicated stroke centres.8 This underlines that clinical 
reality often differs from clinical trial settings. Regis-
ter-based observational data can add clinically focused 
information whether certain warnings from licence 
or variables that have not been well-studied in RCTs—
for example, comedications—matter or not with regard 
to outcome or complications of IVT. Ideally, the results 
from such observational studies will be verified or falsified 
by RCTs. However, with few exceptions (eg, age limit) this 
is unlikely to happen. Thus, register-based data will reflect 
the highest level of evidence, available currently and in 
the foreseeable future. In the last few years, endovascular 
thrombectomy (EVT) in patients with proximal vessel 
occlusion has emerged as another evidence-based treat-
ment option, and acute multimodal imaging methods 
challenge the classical time-window concept.9–11 This 
makes acute stroke care even more complex. As with IVT, 
the benefits of EVT in subgroups of patients under-repre-
sented in clinical trials deserve further research.
In the absence of RCT-based evidence, comprehensive 
observational data will also be useful for individual treat-
ment decisions about IVT and EVT, and in evaluating 
processes of stroke triage and care for IVT or EVT. As a 
prerequisite, such data have to be based on well-main-
tained registries containing a large number of detailed, 
clearly defined and well-characterised variables. TRISP 
(ThRombolysis in Ischemic Stroke Patients) meets these 
prerequisites.
Cohort desCrIPtIon
Aims and objectives of trIsP
TRISP started as a joint initiative of 11 European stroke 
centres in 2010. Initiated by the stroke research team Basel, 
an explorative, research collaborative study was designed 
to study the impact of prior statin treatment on outcomes 
of patients with stroke receiving IVT.12 Currently, TRISP 
comprises 18 European stroke centres (please see online 
supplement for a list of contributors to the TRISP collab-
oration). The TRISP centres cover a distance from Scan-
dinavia to the Mediterranean area and from Western to 
Eastern Europe. TRISP centres constitute high-volume 
IVT centres with a record of comprehensive stroke treat-
ment for several years. All TRISP centres offer treatment 
fulfilling the criteria of Stroke Centres or Stroke Units as 
proposed by the European Stroke Organisation (ESO).13
The major aim of TRISP is to address clinically important 
questions about safety and outcomes of patients with isch-
aemic stroke treated with IVT who are neither covered by 
RCTs nor other large-scale IVT registers such as the Safe 
Implementation of Treatment in Stroke-International 
Stroke Thrombolysis Register (SITS-ISTR) and Get-with-
the-guidelines (GWTG) Stroke.14 15 
design, structure and policy
TRISP operates as an investigator-driven, open platform 
with a clear emphasis on clinical research and data quality. 
TRISP is independent from industry and a non-profit 
collaboration. TRISP particularly aims at supporting 
young researchers. Thus, with the exception of the very 
first paper,12 first authors of the publications invariably 
were young stroke physicians or PhD students.
There is no official chair and no official administra-
tion, board or secretary within the TRISP collaboration. 
Currently, TRISP is coordinated by STE (Basel) and PJN 
(Amsterdam) who are primary contact persons.
Prior to the start of a novel project, standardised 
research proposals stating hypotheses and a statistical 
analysis plan are circulated to all participating centres 
and discussed for scientific content and feasibility. If a 
centre agrees to participate, then the centre contributes 
data for the time period for which they have data on all 
consecutive patients for the key variables of interest (eg, 
usage of a certain comedication). The information of 
the distribution of patients stratified to centre and time 
period is provided as online supplemental material in the 
respective manuscript. If a novel variable of interest needs 
to be added to answer a research question, the research 
proposal needs to describe a definition that allows to 
operationalise retrospective inclusion within the existing 
databases.
Lead of distinct project and authorship
The researcher or researches—usually 1 or 2 (rarely 3)—
who had the idea and rendered the analysis proposal 
take(s) the lead and will get first and senior authorships. 
Coauthorships are attributed taking into account all 
aspects important for the success of a research project. 
This includes not only mere quantitative means (ie, 
number of patients contributed) but also quality of data 
(eg, completeness, though usually high across TRISP 
centres), handling and pooling of the multicentre data; 
maintenance of the pooled data set (including data 
cleaning); statistics, contribution to TRISP in general, 
and intellectual input in details of the design or the anal-
yses of the research project. These criteria are suggestions 
and the researches taking the lead in each project take 
the final responsibility for the distribution of authorships.
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data collection and definitions
Data on the characteristics of patients treated with IVT are 
collected prospectively by all participating centres using 
standardised definitions and a standardised form. Not 
all centres have to provide data on all variables but have 
given a commitment to add missing variables retrospec-
tively, if considered relevant to answer a specific research 
question. The dataset includes information on patients’ 
age, sex and treatment modality (IVT alone, IVT plus 
EVT, EVT alone). Date and time of stroke onset as well as 
onset-to-needle time and door-to-needle time are system-
atically collected. If the exact time of symptom onset is 
unknown or unwitnessed, time from last seen normal 
until application of IVT will be provided. Stroke aeti-
ology will be documented in distinct categories in accor-
dance with the classification of the Trial of Org 10172 in 
Acute Stroke Treatment (TOAST) and classified as due 
to cardioembolic sources, large-artery atherosclerosis, 
small-vessel disease, other determined causes, concur-
rent aetiology or undetermined causes.16 The identified 
‘other determined cause’ will include dissections. Other 
causes will be specified as precisely as possible as free text. 
Patients with final diagnosis other than stroke are classi-
fied as ‘stroke mimics’. Dose of rtPA as well as weight and 
body mass index (BMI) of the patients are documented 
in the majority of centres. Stroke severity at baseline is 
measured using the National Institutes of Health Stroke 
Scale (NIHSS) by experienced stroke physicians. If avail-
able, NIHSS at 24 hours after treatment and at discharge 
from the acute care hospital will be recorded. The func-
tional status of the patient before the index stroke will 
be estimated by the stroke physicians who also indi-
cated and applied IVT using the modified Rankin Scale 
(mRS).17 18 This prestroke mRS scores are based on infor-
mation provided by patients and next-of-kin. Pre-treat-
ment systolic and diastolic blood pressure (mm Hg) are 
also entered in the dataset. In case of more than one 
measurement, the values as close to application of IVT as 
possible will be noted.
Cardiovascular and stroke risk factors include atrial 
fibrillation (known from medical history, detected 
on baseline ECG or during in-hospital cardiac moni-
toring), diabetes mellitus (known from medical history, 
fasting plasma glucose >7.0 mmol/L or 126 mg/dL, 
HbA1c (haemoglobin A1c)>6.5% or pre-existing treat-
ment with antidiabetic drugs), hypercholesterolaemia 
(known from medical history, low-density lipoprotein 
>100 mg/dL (2.6 mmol/L) or treatment with cholester-
ol-lowering drugs), hypertension (known from medical 
history, repeated measurement of systolic blood pressure 
>140 mm Hg and/or diastolic blood pressure >90 mm 
Hg), previous stroke (known from medical history), 
smoking (patients who did not currently smoke were 
divided in non-smokers and past smokers≥2 years) and 
coronary artery disease (known from medical history).19 
Medical history is provided by the patients, next-of-kin or 
family doctors.
Laboratory measures obtained on hospital admission 
include glucose (mmol/L), blood cell counts (platelets, 
haemoglobin, leucocytes), international normalised 
ratio and partial thromboplastin time. In case of use 
of novel oral anticoagulants, specific measurements of 
factor Xa activity, thrombin time or plasma levels of the 
respective drug are recorded, if available. Renal function 
is quantified by the estimated glomerular filtration rate 
(according to Chronic Kidney Disease Epidemiology 
Collaboration formula).20 Comedication used at the time 
of hospital admission prior to IVT is recorded precisely 
(eg, use of antithrombotic drugs and statins). Moreover, 
neuroimaging findings before and after treatment are 
systematically ascertained and comprise imaging modality 
(CT versus MRI) as well as specific imaging findings like 
hyperdense artery sign, presence and extent of early isch-
aemic signs according to the Alberta Stroke Program Early 
CT Score,21 site of vessel occlusion, presence of tandem 
occlusion of ipsilateral carotid artery, recanalisation 
status immediately after EVT and on follow-up imaging 
(quantified according Thrombolysis-In-Cerebral-infarc-
tion (TICI) score,22 TICI 2b/3 indicate successful reca-
nalisation), white matter disease severity,23 presence and 
burden of cerebral microbleeds.23
All patients are monitored for occurrence of haem-
orrhagic transformation. Follow-up imaging is usually 
scheduled at 24–36 hours after treatment or earlier 
in case of clinical worsening. Some centres perform 
follow-up imaging only in case of clinical worsening. The 
definition of symptomatic intracerebral haemorrhage 
(sICH) is in accordance with the definition used in the 
European Cooperative Acute Stroke Study (ECASS) II 
(blood at any site in the brain on the CT scan together 
with documentation of clinical deterioration or adverse 
events indicating clinical worsening or causing a decrease 
in the NIHSS score of 4 or more points).24 The majority 
of centres additionally evaluate type of haemorrhagic 
transformation (haemorrhagic infarction, parenchymal 
haemorrhage), indicate whether the bleeding occurred 
remotely from the infarcted area and document sICH 
according to NINDS, ECASS-II and SITS-MOST (Safe 
Implementation of Thrombolysis in Stroke-Monitoring 
Study) definitions.2 25 26
Functional outcome at 3 months is assessed using the 
mRS.18 The mRS is obtained by telephone calls, postal 
questionnaire or outpatient visits. If patients cannot be 
interviewed, close relatives, nurses or family doctors are 
asked for disability status. More recently, TRISP has been 
extended to include data on EVT, too.
ethical considerations and data protection
Each study project within TRISP has to be approved by the 
ethics committee in the coordination and leading centres 
according to local regulations. It is in the responsibility of 
each participating centre to fulfil the local, regional and 
national legal and ethical requirements. Participating 
centres are responsible to obtain local ethics committee 
approval to collect and pool anonymised data with other 
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centres and to keep a local patient identifier. Once a 
novel project has been approved, data are forwarded to 
the centre leading the respective project. Only strictly 
anonymised data prepared to match the universal data 
collection sheet are accepted.
Patient and public involvement
Patients and public were not involved in the study.
Findings to date
Currently, data on IVT treatments of more than 10 000 
patients are available. Previous publications of TRISP (1) 
provided insight into safety and efficacy of IVT in subgroups 
of patients who were excluded (eg, patients dependent 
on the help of others prior to stroke), under-represented 
or not specifically addressed (eg, dissection as cause, 
impaired renal function, low platelet count, BMI, prior 
use of statins, serotonin reuptake inhibitors, prior use 
of novel oral anticoagulants) in RCTs,12 17 27–34 (2) were 
helpful to evaluate processes of acute stroke care such as 
the meaning of the ‘off-hour-thrombolysis’, IVT during 
‘working hours’ or the variable ‘time’ in clinical prac-
tice35–37 and (3) served to derive, validate and compare 
risk scores for sICH or functional 3-month outcome.38–40
The idea of TRISP is that experienced stroke centres 
with a record and expertise in both (1) usage of throm-
bolysis and (2) maintenance of hospital-based throm-
bolysis databases pool their data. Usually this means, 50 
IVT treatments per year and an IVT rate of >20% of all 
stroke admissions. Completeness of data regarding age, 
sex, initial NIHSS, sICH and mRS at 3 months in >95% 
of consecutive IVT-treated patients is warranted by all 
participating centres. In addition to the characteristics of 
the TRISP centres stated above, an advantage of TRISP is 
the availability of more additional variables than in other 
large-scale registers and the commitment by the collabo-
rators to (1) accuracy and completeness of the data and 
to (2) the willingness to adapt the local databases and 
add quickly new variables retrospectively and prospec-
tively. This enables gaining explorative insights in the 
putative prognostic importance of additional variables 
with unknown impact on outcome or risk of complica-
tions such as sICH. Strengths and limitations of TRISP in 
general and compared with other existing IVT registers 
are discussed below.
strengths and limitations
Strengths of TRISP include (1) the high completeness 
of data with few missing data on 3-month outcome (all 
centres aim to keep this below 5%), (2) large sample sizes 
(several thousands) which reduces the risk of bias and 
allows adjustments for confounders, (3) the systematic 
and standardised data ascertainment which increases the 
homogeneity of the study population, (4) the intrinsic 
motivation of the study personal leads to a high rate of 
completeness of ascertained data sets, contributing to a 
high-quality registry and (5) the dynamic nature of the 
TRISP database due to the commitment of the centres 
to adapt the local database and add variables retrospec-
tively and prospectively. In addition, (6) a large number 
of variables is gathered including those with unknown 
prognostic importance. This allows addressing novel yet 
unmet research questions. Moreover, (7) pooling of indi-
vidual patient data increases generalisability compared 
with single centre studies and (8) the fact that variables 
and outcomes have been collected irrespective of the 
present research question reduces the risk of a bias.
There are other large-scale registers such as the inter-
national SITS-ISTR and the GWTG stroke registry. These 
registers have an unquestioned value and have served 
to address several research questions with high clinical 
impact. The TRISP collaboration does not intend to 
replace these registers but rather to refine the knowledge 
gained by them, to provide additive information and to 
fill gaps not covered yet. An example is the report about 
the usefulness of IVT in patients dependent on the help 
of others prior to stroke,17 which adds to the SITS-ISTR 
report about pre-existing disability.41 Compared with 
the GWTG registry that provides short-term outcomes 
only, TRISP provides systematic assessment of functional 
outcome at 3 months and systematic ascertainment of 
haemorrhagic complications. GWTG is mainly intended 
to be a database for quality control of acute stroke care. 
The possibility of participating centres in TRISP to 
develop individual research projects yields an intrinsic 
motivation to maintain a high data quality. Another 
difference of TRISP compared with SITS-ISTR (and also 
GWTG) are the characteristics of the sites that contribute 
data. In TRISP, solely experienced centres participate, 
while in SITS-ISTR and GWTG also low-volume centres 
with fewer IVT treatments per year enter their data.
Limitations are inherent to the design of TRISP. (1) 
Data are derived from registers that are neither moni-
tored nor randomised. Usually, there will be no control 
group without IVT which disallows the assessment of effec-
tiveness of IVT in study populations. (2) As true for all 
observational studies, TRISP analyses have a higher risk 
of bias than RCTs. Thus, we urge to a cautious interpre-
tation of findings and observations. (3) All TRISP centres 
are experienced in stroke treatment. This includes in 
particular the use of IVT and increasingly EVT, too. This 
expertise implies—as a downside—a limited generalis-
ability of TRISP findings to all stroke providers with less 
expertise and less advanced setting. (4) The majority of 
our included patients are Caucasians. Thus, we cannot 
compare ethnical differences, but might have the poten-
tial to set up further collaborations in the future. (5) 
Centres from Eastern Europe are relatively under-repre-
sented in TRISP. We encourage participation of centres 
from Eastern Europe in future projects to overcome this 
limitation and further increase generalisability of findings 
from TRISP. (6) Currently, there is no ‘core lab’ to validate 
haemorrhagic complications and 3-month mRS ratings. As 
valid for other registries like SITS and GWTG, local inter-
pretation of outcome data may differ between sites. Since 
TRISP centres are high-volume centres with long-standing 
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experience in maintaining IVT databases, this bias is likely 
to be smaller than in these other registries.
Collaboration
The TRISP collaboration welcomes participation and 
project proposals of further centres fulfilling the require-
ments stated in box 1. The currently participating centres 
have agreed to fulfil the prerequisites that are summarised 
in box 1. Participation in other registries does not exclude 
from participation in the TRIPS collaboration. In order 
to participate or suggest a novel project, please contact 
the TRISP coordinating centres Basel or Amsterdam 
(see  corresponding author or list of contributors in 
the online supplements). On request, the standardised 
data collection form and project proposal form will be 
forwarded. Only strictly anonymised data are used and 
can be included. Data sharing is restricted to non-com-
mercial, purely academic purposes only. Furthermore, 
data ownership remains at the centre/physician by whom 
the data were originally obtained.
outlook
Currently, several further TRISP projects are ongoing or 
planned. Given the potential of brain MRI to provide more 
prognostic information than plain CT (eg, presence of 
large infarct core, presence of cerebral microbleeds),42 43 
centres with regular MRI-based application of IVT (ie, 
Berlin, Bern, Lille and Paris) can offer to pool data within 
the subsection ‘TRISP MRI’, while others (eg, Basel) can 
focus on advanced CT imaging (TRISP-CT).
In the light of the recent positive trials of EVT in ante-
rior circulation stroke the subsection ‘TRISP endovascular’ 
is operating since 2018. A standardised form including 
additional procedure-related variables was set up and 
agreed on during the ESO conference in 2018.
An official meeting will be scheduled annually during 
the respective ESO Conference. The aim is to discuss 
progress of ongoing projects as well as feasibility and 
scientific value of new project proposals. Summarising 
minutes are circulated to all participating centres.
summary
The TRISP collaboration is an open platform dedicated to 
conduct joint research projects in patients with ischaemic 
stroke treated with IVT and also with EVT in the future. 
TRISP aims to increase knowledge regarding safety and 
outcomes after IVT and EVT and to evaluate processes 
of care. As shown in previous publications, TRISP has 
the potential to provide observational information on 
treatment of patients derived from daily clinical practice. 
Prospective and standardised documentation of indi-
vidual patient data according to consensus definitions is 
a major requirement to maintain the quality of registers 
that contribute to TRISP. TRISP welcomes participation 
and project proposals of further centres fulfilling the 
requirements stated above.
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box 1 universal standards and requirements for 
contributing to trIsP*
 ► Prospective registry of consecutive patients with systematic check-
up of missing cases.
 ► Comprehensive collection of baseline characteristics according to 
consensus definitions stated in this manuscript.
 ► Prospective assessment of haemorrhagic complications (symptom-
atic intracerebral haemorrhage according to ECASS II criteria) and 
functional outcome at 3 months (according to the modified Rankin 
Scale; either telephone interview, postal questionnaire or clinical 
follow-up visit).
 ► Approval of institutional review board to maintain the respective IVT 
database and to obtain 3-month follow-up data.
 ► TRISP centres are comprehensive stroke centres with high-vol-
ume IVT applications and usually University hospitals or affiliated to 
University hospitals.
 ► Treatment of patients with acute ischaemic stroke with IVT accord-
ing to guidelines valid at the relevant time (http://www. eso- stroke. 
org/ eso- stroke/ education/ guidelines. html) or documentation of de-
viation therefrom.
*TRISP welcomes participation and project proposals of further centres fulfilling 
the commitment and the outlined requirements.
Note: ECASS II, European Cooperative Acute Stroke Study II; IVT, intravenous 
thrombolysis; TRISP, ThRombolysis in Ischemic Stroke  Patients. 
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